BIOMAT Database Logo BIOMAT Database Logo

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. 1989

Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Department of Surgery, New York Hospital, Cornell Medical Center, New York 10021.

Cytokines secreted in response to invading micro-organisms are important mediators of detrimental hemodynamic and metabolic changes in the host. To test whether cachectin/TNF plays a role in triggering release of other cytokines in the setting of infection, anesthetized baboons were passively immunized against systemic cachectin/TNF before infusion of a LD100 dose of live Escherichia coli. Bacteremia led to significant increases in circulating levels of cachectin/TNF, IL-1 beta, and IL-6. Although bacterial endotoxin/lipopolysaccharide is a potent stimulus for the synthesis and release of IL-1 and IL-6 in vitro, specific neutralization of cachectin/TNF in vivo with mAb pretreatment significantly attenuated both the IL-1 beta and the IL-6 responses despite fulminant overwhelming bacteremia. These data suggest that cachectin/TNF is essential for the initiation or amplification of IL-1 and IL-6 release during lethal gram-negative septic shock syndrome.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D010215 Papio A genus of the subfamily CERCOPITHECINAE, family CERCOPITHECIDAE, consisting of five named species: PAPIO URSINUS (chacma baboon), PAPIO CYNOCEPHALUS (yellow baboon), PAPIO PAPIO (western baboon), PAPIO ANUBIS (or olive baboon), and PAPIO HAMADRYAS (hamadryas baboon). Members of the Papio genus inhabit open woodland, savannahs, grassland, and rocky hill country. Some authors consider MANDRILLUS a subgenus of Papio. Baboons,Baboons, Savanna,Savanna Baboons,Baboon,Baboon, Savanna,Papios,Savanna Baboon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012772 Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status. Endotoxin Shock,Septic Shock,Shock, Endotoxic,Shock, Toxic,Toxic Shock,Toxic Shock Syndrome,Endotoxin Shocks,Shock Syndrome, Toxic,Shock, Endotoxin,Shocks, Endotoxin,Toxic Shock Syndromes
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D018805 Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK. Bloodstream Infection,Pyaemia,Pyemia,Pyohemia,Blood Poisoning,Poisoning, Blood,Septicemia,Severe Sepsis,Blood Poisonings,Bloodstream Infections,Infection, Bloodstream,Poisonings, Blood,Pyaemias,Pyemias,Pyohemias,Sepsis, Severe,Septicemias

Related Publications

Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation.
August 1990, The Journal of experimental medicine,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.
June 1988, The Journal of experimental medicine,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Neonatal tumor necrosis factor, interleukin-1 alpha, interleukin-1 beta, and interleukin-6 response to infection.
July 1994, American journal of perinatology,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 levels in febrile, young children with and without occult bacteremia.
December 1999, Pediatrics,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats.
October 2002, European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
[Tumor necrosis factor/cachectin].
January 1990, Acta haematologica Polonica,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Cachectin/tumor necrosis factor.
June 1996, JPMA. The Journal of the Pakistan Medical Association,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor.
June 1991, Surgery,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection.
June 1989, The Journal of experimental medicine,
Y Fong, and K J Tracey, and L L Moldawer, and D G Hesse, and K B Manogue, and J S Kenney, and A T Lee, and G C Kuo, and A C Allison, and S F Lowry
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.
June 1986, The Journal of experimental medicine,
Copied contents to your clipboard!